10 mg of semaglutide: does this dose exist, and what does it mean for your treatment?

Step 1: understand which semaglutide product and schedule applies to weight management

Semaglutide comes in several distinct forms in the UK, and they are not interchangeable. Wegovy is the injectable form licensed for weight management, available as a once-weekly subcutaneous injection. Its dose ladder runs 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg, each held for roughly four weeks before a prescriber considers moving up. Since January 2026 a 7.2 mg maintenance dose has also been licensed; the dedicated single-dose 7.2 mg pen received MHRA approval in April 2026. That is the full range. No rung reads 10 mg.

Then there is the Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight loss. Its schedule is 1.5 mg, 4 mg, 9 mg, and 25 mg daily, taken first thing each morning on an empty stomach with a small amount of plain water, waiting at least 30 minutes before eating or drinking anything else. Again, no 10 mg step. The Wegovy overview page covers both forms in detail.

Rybelsus (also oral semaglutide) uses 3 mg, 7 mg, and 14 mg tablets, but it is licensed for type 2 diabetes, not weight management. Those three strengths sometimes confuse readers searching for semaglutide tablet doses, but they belong to an entirely different licensed indication. Swapping them in is not clinically appropriate, and no UK prescriber should offer them for weight loss.

Step 2: work out where a "10 mg" figure most likely came from

Three sources account for almost every "10 mg semaglutide" query. The first is a misreading of dose units: semaglutide strengths are stated in milligrams, but some older or international product labelling uses micrograms for early doses, and unit confusion is common. The second is content that has mixed up the Rybelsus tablet strengths (3/7/14 mg) with the Wegovy injection schedule. The third (and the one that matters most for safety) is unlicensed product being described with invented or arbitrary dose numbers.

The MHRA has warned repeatedly about counterfeit and unlicensed weight-loss medicines sold online, including fake pens containing wrong active ingredients at wrong concentrations. A product labelled "semaglutide 10 mg" does not correspond to any authorised UK medicine; if you have encountered one being sold, the right move is to report it at the MHRA's Yellow Card scheme. You can also verify any online pharmacy you are considering by looking it up on the GPhC pharmacy register, a two-minute check that tells you whether the service operates under legitimate UK regulatory oversight.

If your question arose from something a prescriber said, it is worth going back to clarify. Dose discussions in clinic sometimes involve cumulative weekly totals or other contexts, a quick follow-up call will clear it up.

Step 3: understand what the licensed schedule is actually designed to do

The Wegovy injection schedule is designed the way it is for a reason. Starting at 0.25 mg gives the digestive system time to adapt; nausea and other gastrointestinal effects are most common early on and in the days after a dose increase. The prescriber-led titration means dose changes happen when you are ready, not on a fixed calendar. Results from the STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% at 68 weeks on 2.4 mg. The newer 7.2 mg data suggests around 20.7% average loss at 72 weeks.

For the oral Wegovy tablet, phase 3 trial data (OASIS 4) reported approximately 13.6% average weight loss over 64 weeks versus around 2.4% on placebo, rising to roughly 17% among participants who adhered fully. Details on how results differ by dose and form are covered on the semaglutide weight-loss percentage page. Context on how costs vary across the treatment journey is on the Wegovy cost page.

The full dose schedule, injection sites, storage guidance and missed-dose advice are set out in the Patient Information Leaflet that comes with your prescription. A prescriber at our GPhC-registered pharmacy can walk through all of this at your consultation, prescription-only medicines require that clinical assessment before any dose decision is made. The Wegovy doses guide sets out each step in plain terms if you want a reference point before that conversation.

Step 4: what to do if you have further questions about semaglutide dosing

If you are already on Wegovy and wondering whether your current dose is working, or whether a higher dose is appropriate, that question belongs with your prescriber, not a search engine. Dose changes require a clinical review of your response and tolerance; they are not something to self-direct. Our FAQs page covers some common dosing questions, and if you want to speak to the team directly, the contact page lists your options.

If you are researching semaglutide for the first time and trying to understand where treatment might start, have a look at the 5 mg semaglutide page for context on one of the mid-range injectable steps, or explore the weight-loss treatments overview for a broader picture of what is available. When you are ready to find out whether semaglutide is clinically appropriate for you, check your eligibility with our prescribers, and if you want more detail on how the titration works before your consultation, the semaglutide 1 mg page explains what to expect at that particular point in the dose schedule. A named clinician, not software, reads every consultation the same day it is submitted.